| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BMS-345541 | GDSC1000 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | Dasatinib | FIMM | pan-cancer | AAC | -0.014 | 0.9 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.0023 | 0.9 |